ADS 8902

Drug Profile

ADS 8902

Alternative Names: ADS-8902; Amantadine/ribavirin + neuraminidase inhibitor - Adamas; Amantadine/ribavirin + oseltamivir - Adamas; TCAD (amantadine/ribavirin and oseltamivir phosphate)

Latest Information Update: 18 May 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Adamas Pharmaceuticals
  • Class Acetamides; Adamantanes; Antivirals; Cyclohexenes; Organic bridged compounds; Ribonucleosides; Small molecules
  • Mechanism of Action Dopamine receptor agonists; Ion channel modulators; Neuraminidase inhibitors; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Influenza A virus H1N1 subtype; Influenza A virus infections

Most Recent Events

  • 18 May 2012 Discontinued - Phase-II for Influenza A virus infections in Canada (PO)
  • 18 May 2012 Discontinued - Phase-II for Influenza A virus infections in Europe (PO)
  • 18 May 2012 Discontinued - Phase-II for Influenza A virus infections in Southern Hemisphere (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top